None listed
Conditions
Brief summary
This study aims to determine if curcumin can delay progression of chronic lymphocytic leukemia in patients with early disease. Who is it for? You may be eligible join this study if you are a patient over the age of 40 who has been diagnosed with stage 0/1 chronic lymphocytic leukemia (absolute lymphocyte count > 20x10^9 lymphocytes/L). Trial details All participants in this trial will be given curcumin (derived from the spice turmeric) orally at a dose of 2g/day for 6 months. Participants will be assessed by blood test every 2 months over the 6 month study period in order to determine treatment response such as absolute change in lymphocyte count.
Interventions
Curcumin, derived from the spice turmeric, has anticancer and anti-inflammatory properties. Curcumin will be administered orally at a dose of 2g/day. Patients will be monitored at 2 monthly intervals for a period of six months. Blood samples will be collected at each visit. Lymphocyte count, surface leukocyte markers,CRP and ESR, liver function will be assessed by blood tests. Compliance will be ascertained by questioning the patient.
Sponsors
Southern Sydney Haematology
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Male or female patients over the age of 40 who have been diagnosed with stage 0/1 chronic lymphocytic leukemia (absolute lymphocyte count > 20x10 (9)lymphocytes/L).
Exclusion criteria
1)Patients who are being actively treated. 2)Requirement for major surgery 3) Patients with diabetes 4) Patients on warfarin 5) Patients with GORD
Outcome results
None listed